Novartis AG’s Gilenya Given Final Approval by UK’s Cost Agency

Novartis AG (NOVN)s multiple sclerosis pill Gilenya won final approval from Englands health-cost agency for some patients after the company agreed to a discounted price. The National Institute for Hea…
Read the full story: BioSpace.com Featured News